2023
DOI: 10.1016/s2666-5247(23)00216-1
|View full text |Cite
|
Sign up to set email alerts
|

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 29 publications
1
1
0
Order By: Relevance
“…Therefore, a homogenous or heterogeneous boosting strategy may be able to combat emerging variants such as Omicron, with the advantage that it can improve the titers of neutralizing antibodies as well as provide diverse epitopes that play a key role in both B and T-cell responses ( 38 ). These findings may also explain why moderate neutralizing antibodies could still provide some in vivo cross-protection using the boosting strategy in our study and clinical trials reported elsewhere ( 39 , 40 ).…”
Section: Discussionsupporting
confidence: 71%
“…Therefore, a homogenous or heterogeneous boosting strategy may be able to combat emerging variants such as Omicron, with the advantage that it can improve the titers of neutralizing antibodies as well as provide diverse epitopes that play a key role in both B and T-cell responses ( 38 ). These findings may also explain why moderate neutralizing antibodies could still provide some in vivo cross-protection using the boosting strategy in our study and clinical trials reported elsewhere ( 39 , 40 ).…”
Section: Discussionsupporting
confidence: 71%
“…COVID-19 vaccines may also provide a certain level of cross-protection against related coronaviruses [ 5 ]. Additionally, studies are exploring the feasibility and efficacy of heterologous vaccination, where different types of vaccines are administered in a mixed-dose schedule [ 6 ]. These approaches could offer flexibility in vaccination campaigns and address supply chain challenges.…”
mentioning
confidence: 99%